Valuation: Cerus Corporation

Market Cap 61Cr 53Cr 49Cr 45Cr 85Cr 5.84TCr 86Cr 586.37Cr 229.5Cr 2.86TCr 227.15Cr 222.26Cr 9.87TCr P/E 2026 *
-90.6x
P/E 2027 * -907x
Enterprise Value 61Cr 53Cr 49Cr 45Cr 85Cr 5.84TCr 86Cr 586.37Cr 229.5Cr 2.86TCr 227.15Cr 222.26Cr 9.87TCr EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.33x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day-3.21%
1 week-5.03%
Current month+3.42%
1 month+16.15%
3 months+55.67%
6 months+15.27%
Current year+46.60%
1 week 3.01
Extreme 3.01
3.25
1 month 2.56
Extreme 2.56
3.47
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-16,666 0.0083%
01/07/26 Free

Chief Executive Officer

9,24,215 0.4613%
30/06/26 Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-3.21%-5.03%+111.19%+4.86% 63Cr
-1.70%-2.28%-21.74%+4.62% 12TCr
-0.49%-2.78%-1.63%-7.02% 1.27TCr
-0.15%-2.54%+58.63%+104.19% 898.73Cr
+8.70%+15.33%-41.19%-66.00% 445.55Cr
-1.11%-9.10%+0.60%+39.57% 267.61Cr
-0.70%-1.80%-8.42%-21.88% 165.06Cr
+0.89%-7.06%-23.89%-32.36% 159.41Cr
-2.03%+3.75%-2.53%-59.29% 155.99Cr
Average +0.02%-1.33%+7.89%-3.70% 1.72TCr
Weighted average by Cap. -1.17%-1.87%-14.75%+6.71%

Financials

2026 *2027 *
Net sales 24Cr 21Cr 19Cr 18Cr 34Cr 2.3TCr 34Cr 230.74Cr 90Cr 1.12TCr 89Cr 87Cr 3.88TCr 26Cr 23Cr 21Cr 19Cr 37Cr 2.51TCr 37Cr 251.78Cr 99Cr 1.23TCr 98Cr 95Cr 4.24TCr
Net income -62.38L -54.65L -50.74L -46.62L -87.86L -60Cr -89.15L -6.04Cr -2.37Cr -29Cr -2.34Cr -2.29Cr -101.74Cr -5L -4L -4L -4L -7L -4.63Cr -7L -46.45L -18.18L -2.26Cr -17.99L -17.61L -7.82Cr
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
22/26/22 $3.020 -3.21% 21,86,376
21/26/21 $3.120 -0.95% 28,49,612
20/26/20 $3.150 +0.64% 19,21,525
17/26/17 $3.130 -2.49% 24,28,479
16/26/16 $3.210 +0.94% 18,52,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.020USD
Average target price
4.667USD
Spread / Average Target
+54.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock